Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CD19 t-haNK in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05618925Phase 1Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CD19t-haNK in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoint: Primary Outcome Measures at 30 days. Started Aug 2025; status: recruiting.
02
Drugs
CD19t-haNK
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05618925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618925.